TailorMed Helps Expand Medication Access and Support for ZENBEXUS™ (iberdomide)

For patients starting a new oral oncology therapy, the space between a prescription and the first fill is where too many stall. Cost, paperwork, and program complexity slow people down at the exact moment treatment should begin.

TailorMed, the Medication Success Platform, now enables eligible patients to digitally enroll in the ZENBEXUS Co-pay Program through its network of oncology providers and dispensing clinics, in collaboration with Bristol Myers Squibb.

ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone is approved for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

TailorMed’s platform integrates into the workflows care teams already use, matches patients to available resources, and streamlines enrollment, helping teams reduce delays and improve patient outcomes without adding complexity. Provider networks can use TailorMed Core and its Express Enroll capabilities to instantly screen patients and auto-populate documentation. For practices dispensing oral specialty medications, TailorMed Connect acts as a medication journey companion, reducing first-fill abandonment and supporting long-term adherence at the point of dispensing.

{{testimonial}}

TailorMed supports the full lifecycle of medication access, combining enterprise workflow tools with patient-facing channels. This connected approach brings greater visibility and coordination to a historically fragmented process, helping ensure support reaches patients. The integrated ZENBEXUS enrollment experience is now active across TailorMed’s network, which spans 945+ hospitals, 4,700+ clinics, and 3,100+ pharmacies nationwide.